Cure My Disease

Don't miss your cure!

 Log in / Sign up

Silent strokes in sickle cell adults: a hidden crisis revealed

NCT ID NCT03376893

Knowledge-focused Sponsor: Vanderbilt University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 102 adults with sickle cell disease to track how often silent and overt strokes occur. Participants undergo regular MRI scans and neurological exams over 3.5 years. The goal is to gather data that could lead to the first stroke prevention trials specifically for adults with this condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could provide the data needed to design the first clinical trials for stroke prevention in adults with sickle cell disease.
What could go wrong
This is an observational study, not a treatment trial. It only collects information and does not test any new therapy, so it cannot directly improve health outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

102 people

The number who actually took part.

Started

Jun 2017

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants will be patient volunteers from the sickle cell disease clinics of participating study sites.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participants with sickle cell disease on hemoglobin analysis and/or other confirmatory documentation of phenotype 2. Patients ≥ 18 years of age 3. Patients followed regularly (at least two visits per year) in the hematology clinics 4. Patients who have demonstrated adherence with follow-up visits for ≥ 3 years 5. Patients willing to be followed prospectively for a minimum of 3.5 years and agree to a standard care exit MRI/MRA of the brain, as well as MRI/MRA every 12 to 18 months or participation in VUMC AHA trial with Dr. Jordan as PI. These are adults with SCA aged 18-40 years at study entry, enrolled with any infarct status (none, SCI or overt stroke) and followed prospectively. 6. Willingness to comply with study protocol, routine clinic visits Exclusion criteria: 1. Participants judged to be non-compliant by the hematologist based on previous experience in terms of clinic appointments and following advice 2. Participants with contraindications to MRI, including individuals with MRI-incompatible foreign metal objects

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anemia, sickle cell are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sickle cell disease sickle cell-beta plus-thalassemia sickle cell-beta zero-thalassemia sickle cell-beta-thalassemia disease syndrome stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anemia, sickle cell Sickle cell disease Sickle cell thalassemia Sickle cell-BETA0-thalassemia Stroke

Contacts and locations

Locations

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35233, United States

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232-9000, United States

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.